AIP

Arteris, Inc. (AIP) - Q3 2025 10-Q Summary

Business Context and Reporting Period

This summary covers the quarterly period ended September 30, 2025. Arteris, Inc. is a provider of semiconductor system IP, specifically interconnect and Networks-on-Chip (NoC) technology, used in System-on-Chip (SoC) designs. The company operates as a single reporting segment with offices globally, including significant operations in the United States, China, and Europe.

Key Financial Metrics

Note: Cash and investments include $17.4 million in cash equivalents, $21.6 million in short-term investments, and $17.2 million in long-term investments as of September 30, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Total revenue increased 18% year-over-year (YoY) in Q3 and 19% for the nine-month period. This was driven by an 18% increase in licensing, support, and maintenance revenue and a 28% increase in variable royalties.
• Expense Increases: Operating expenses rose 15% YoY in Q3. Sales and marketing expenses increased 38% due to higher headcount and stock-based compensation. R&D expenses increased 6% due to employee-related costs.
• Stock-Based Compensation: Total stock-based compensation expense increased to $5.0 million in Q3 2025 from $4.4 million in Q3 2024.
• Equity Method Investment: The company recorded a loss of $0.5 million from its equity method investment in Transchip Technology (Nanjing) Co., Ltd. for the quarter.

Outlook, Risks, and Management Commentary

• Key Performance Indicators: As of September 30, 2025, Annual Contract Value (ACV) was $69.4 million (up from $56.4 million in 2024). Confirmed Design Starts were 23 in Q3 2025, compared to 14 in Q3 2024. Remaining Performance Obligations (RPO) stood at $104.7 million.
• Liquidity: Management believes existing cash, investments, and operating cash flows are sufficient to meet requirements for at least the next 12 months. However, the company has an accumulated deficit of $163.1 million and may require additional financing in the future.
• Regulatory Risks: Significant risks include U.S. export controls and trade restrictions affecting business in China, which accounted for 24.4% of revenue in the first nine months of 2025. The company notes that revenue from China is expected to decrease due to these restrictions.
• Legal Proceedings: A patent infringement complaint filed by Network System Technologies, LLC (NST) was dismissed without prejudice in September 2024; no new claims have been made as of the filing date.
• Equity Method Investment Risk: The company's investment in Transchip is dependent on the investee's ability to raise additional capital to continue operations.

Investor Verification Checklist

• China Exposure: Verify the specific impact of U.S. export controls on the 24.4% of revenue derived from China and the timeline for potential revenue declines.
• Path to Profitability: Assess the sustainability of the 90% gross margin against rising operating expenses (particularly S&M and R&D) and the timeline to reduce the accumulated deficit of $163.1 million.
• Transchip Investment: Monitor the financial health of the equity method investee (Transchip) and the potential for dilution or impairment given its reliance on external capital.
• Deferred Revenue: Review the $85.9 million deferred revenue balance and the $101.1 million in non-cancelable contracted performance obligations to gauge future revenue visibility.
• Stock-Based Compensation: Evaluate the impact of the $13.8 million stock-based compensation expense (9M 2025) on future cash burn and dilution.